Nothing said here yet.
to join the conversation.
The FDA is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.
Craig McDonald said on Wednesday that in patients in the HOPE-3 trial with weakened hearts, Deramiocel treatment produced “essentially complete stabilization” over a year.
Capricor Therapeutics (NASDAQ:CAPR) presented updated clinical data for deramiocel in Duchenne muscular dystrophy, or DMD, including two-year open-label extension results from its Phase III HOPE-3 study and additional statistical analyses submitted to the…
Capricor’s Phase 3 HOPE-3 open-label extension data shows significant improvement in upper limb decline, but H.C. Wainwright said it did not remove the statistical uncertainty from the original trial.
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year-
The company is slated to orally present long-term trial results of deramiocel at the World Muscle Society congress in Hiroshima on October 3.
Patients switching from placebo to Deramiocel recorded 76% slower upper-limb decline and 66% slower decline in elbow-related function.
New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox Kilsheimer LLP announces that...
Capricor Therapeutics is back in focus after fresh analyst work led to sharply revised price targets, with some models now pointing to fair value estimates as high as US$27.00 from US$4.38.
New York, New York--(Newsfile Corp. - September 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ:
New York, New York--(Newsfile Corp. - September 21, 2026) - Kaplan Fox Kilsheimer LLP announces that...
– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA –